Publications by authors named "Jane Bold"

Claim this Profile
S
Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.
Titia Q Ruijs, Catherine M K E de Cuba, Jules A A C Heuberger, John Hutchison, Jane Bold

Clin Pharmacol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.
Thomas Skjærlund Grønnebæk, Helga Haahr-Lillevang, Martin Skov, Kristina Kelly, Nathan R Kerr, Jane Bold

Ann Clin Transl Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis.
Martin Skov, Titia Q Ruijs, Thomas S Grønnebæk, Marianne Skals, Anders Riisager, Jane Bold

Sci Transl Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis